Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream

Fernández–Vozmediano, J.M.; Armario-Hita, J.C.

doi:10.1016/j.jaad.2004.11.024

Cited by 13 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recurrence aside, there have been several reports of Imiquimod triggering keratoacanthomas and indeed infiltrating or aggressive SCC [22]. There has been also a report of a pulmonary embolism occurring after Imiquimod use [23].…”

Section: Discussionmentioning

confidence: 99%

Melanoma Arising after Imiquimod Use

Paul

2014

Case Reports in Medicine

View full text Add to dashboard Cite

Imiquimod belongs to the class of 1H-imidazo-[4,5-c]quinolones—drugs originally developed as nucleoside analogues with the aim of finding new potential antiviral agents (Harrison et al., 1988). Indeed, Imiquimod was first released as treatment for genital warts before its actions against skin cancer were studied. Imiquimod is a relatively small sized molecule (Mr = 240.3) and is hydrophobic, allowing it to penetrate the skin epidermal barrier and therefore making it suitable for topical formulations (Gerster et al., 2005). Imiquimod has shown itself effective against skin cancers and precancerous lesions, especially basal cell cancers and actinic keratosis (Salasche et al., 2002, Beutner et al., 1999). There have been reports of Imiquimod being used as topical treatment against cutaneous metastases of melanoma and some authors have reported its use as first-line therapy against melanoma in situ (Smyth et al., 2011, Gagnon, 2011). We report a case of an invasive malignant melanoma arising de novo at the specific site of application of Imiquimod (Aldara cream 5%) for a biopsy-proven superficial BCC. Therefore while Imiquimod has added to our topical armamentarium against skin cancer, care must be exercised in prescribing this treatment and it is especially important to follow up patients regularly.

show abstract

Section: Discussionmentioning

confidence: 99%

Melanoma Arising after Imiquimod Use

Paul

2014

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…The most common of those weird systemic side effects are influenza-like symptoms and headache. A review of the literature revealed lots of unusual adverse reactions related to the topical use of this drug, which are summarized in table 1[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. …”

Section: Discussionmentioning

confidence: 99%

“…Even though the mechanism is unknown, a Koebner phenomenon has been proposed. Although this drug seems to have a role in the treatment of actinic keratosis, once it is used a strict and long follow-up of the patients is recommended due to the risk of development of a malignant neoplasm in a previously treated site [21]. …”

Section: Discussionmentioning

confidence: 99%

Acute Renal Failure Caused by Imiquimod 5% Cream in a Renal Transplant Patient: Review of the Literature on Side Effects of Imiquimod

Santos‐Juanes

Esteve²,

Mas-Vidal³

et al. 2011

Dermatology

View full text Add to dashboard Cite

Imiquimod is an immunomodulator of the imidazoquinoline group which possesses antiviral and antitumour activities. Although its mechanism of action has not been entirely elucidated yet, imiquimod 5% cream has been shown to be an efficient, long-lasting and safe therapy for multiple actinic keratoses in non-immunosuppressed patients and in transplant recipients. We report the case of a 44-year-old patient with a third renal transplant who developed an acute tubular necrosis confirmed by renal biopsy after the use of imiquimod 5% cream. The result of a literature search revealed a wide variety of side effects attributable to the use of imiquimod.

show abstract

“…However, in that reported case, imiquimod was used for the treatment of solar keratosis. 5 In contrast to case 1, the second case concerns a patient with CLL who developed well-differentiated SCC within SCC in situ of the leg that had failed therapy with cryotherapy and imiquimod. Chronic lymphocytic leukaemia is known to be associated with immunodeficiency and immune dysregulation.…”

Section: Discussionmentioning

confidence: 99%

Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream

Goh

2006

Aust J Dermatology

View full text Add to dashboard Cite

Squamous cell carcinoma in situ has the potential to progress to invasive squamous cell carcinoma. This report presents two cases of punch biopsy-proven squamous cell carcinoma in situ, treated with once-daily application of 5% imiquimod cream for 6 weeks. Both patients developed moderate local inflammatory reactions during treatment. The first patient demonstrated clinical clearance of the scalp lesion after treatment. Two months later, he re-presented with a subcutaneous nodule at the same site. Histology was consistent with recurrent squamous cell carcinoma. Five months following excision of the recurrent tumour, he presented with metastatic squamous cell carcinoma to a cervical lymph node. The second patient had low-grade chronic lymphocytic leukaemia and presented with squamous cell carcinoma in situ of the leg that failed to clear clinically after treatment with imiquimod. He presented 4 months later with a focus of invasive squamous cell carcinoma within the lesion.

show abstract

Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream

Cited by 13 publications

References 5 publications

Melanoma Arising after Imiquimod Use

Melanoma Arising after Imiquimod Use

Acute Renal Failure Caused by Imiquimod 5% Cream in a Renal Transplant Patient: Review of the Literature on Side Effects of Imiquimod

Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream

Contact Info

Product

Resources

About